ClinicalTrials.gg
CompletedNCT01474772Updated Jan 28, 2021Results posted

Efficacy and Safety Study of Pregabalin in the Treatment of Pain on Walking in Patients With Diabetic Peripheral Neuropathy (DPN)

A Phase 3 interventional study of Pregabalin and placebo in Diabetic Peripheral Neuropathy, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 45 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-28.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
217
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The intent of this study is to treat subjects with painful Diabetic Peripheral Neuropathy (DPN) who also have pain on walking and to determine whether or not pregabalin demonstrates improvement relative to placebo on the following: reducing DPN pain, reducing pain on walking, and providing other benefits associated with daily activities and quality of life.

02

Conditions studied

  • Diabetic Peripheral Neuropathy

Keywords

  • Diabetic Peripheral Neuropathy
  • Pain on Walking
  • Pregabalin
03

In context

Lead sponsor

Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.

First submitted before Pfizer's Upjohn has merged with Mylan to form Viatris Inc. became part of Viatris Inc..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women who are at least 18 years old.
  • Diagnosis of painful diabetic peripheral neuropathy.
  • Pain on walking.

Exclusion criteria

Exclusion Criteria:

  • Inability to walk 50 feet on a flat surface.
  • Pain on walking due to conditions other than diabetic peripheral neuropathy.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
217 participants (actual)

Study arms

  • Experimental
    Pregabain

    Drug: Pregabalin

  • Placebo comparator
    Placebo

    Other: placebo

Interventions

  • 150-300 mg/day given in 3 divided doses as capsules

    Also known as: Lyrica

  • Otherplacebo

    matching placebo capsules given in 3 divided doses

06

What researchers measure

Primary outcomes

  1. Average Diabetic Peripheral Neuropathy (DPN) Pain Based on a Numeric Rating Scale (NRS) Over the Last 7 Days of Each Treatment Period (Week 6 of Each Treatment Period)

    The daily pain diary consisted of an 11-point numeric scale ranging from 0 ("no pain") to 10 ("worst possible pain"). Participants described their pain during the past 24 hours by having chosen the appropriate number between 0 and 10. Self-assessment was performed daily each evening before bedtime (6.00 pm to midnight) on the telephone via Interactive Voice Recognition System (IVRS). The endpoint mean pain score was defined as the mean of the last 7 daily diary pain ratings while taking study medication in each treatment period - Period 1 and Period 2, respectively. A rating of 1 - 3 was considered as mild pain; 4 - 6 as moderate pain; and 7 - 10 as severe pain.

    Time frame: End of Period (includes both Visits 6 and 11)

  2. DPN Pain on Walking Based on a 11-point NRS of Each Treatment Period (Week 6 of Each Treatment Period)

    The post-test DPN pain on walking NRS consisted of an 11-point numeric scale ranging from 0 ("no pain") to 10 ("worst possible pain"). Participants described their DPN pain in their legs and/or feet while walking during the 50-foot walk test by choosing the appropriate number between 0 and 10. The post-test DPN pain on walking NRS was completed by the participant using paper-pen administration immediately after completing the 50-foot walk test at the end of each treatment period - Period 1 and Period 2, respectively. A rating of 1 - 3 was considered as mild pain; 4 - 6 as moderate pain; and 7 - 10 as severe pain.

    Time frame: End of Period (includes both Visits 6 and 11)

Secondary outcomes

  1. Percentage of Participants Achieving 30% Reduction in Mean DPN Pain Score From Baseline at the End of Each Treatment Period (Week 6 of Each Treatment Period)

    The daily pain diary consisted of an 11-point numeric scale ranging from 0 ("no pain") to 10 ("worst possible pain"). Participants described their pain during the past 24 hours by having chosen the appropriate number between 0 and 10. Self-assessment was performed daily each evening before bedtime (6.00 pm to midnight) on the telephone via IVRS. The endpoint mean pain score was defined as the mean of the last 7 daily diary pain ratings while taking study medication in each treatment period - Period 1 and Period 2, respectively. A rating of 1 - 3 was considered as mild pain; 4 - 6 as moderate pain; and 7 - 10 as severe pain.

    Time frame: End of Period (includes both Visits 6 and 11)

  2. Percentage of Participants Achieving 50% Reduction in Mean DPN Pain Score From Baseline at the End of Each Treatment Period (Week 6 of Each Treatment Period)

    The daily pain diary consisted of an 11-point numeric scale ranging from 0 ("no pain") to 10 ("worst possible pain"). Participants described their pain during the past 24 hours by having chosen the appropriate number between 0 and 10. Self-assessment was performed daily each evening before bedtime (6.00 pm to midnight) on the telephone via IVRS. The endpoint mean pain score was defined as the mean of the last 7 daily diary pain ratings while taking study medication in each treatment period - Period 1 and Period 2, respectively. A rating of 1 - 3 was considered as mild pain; 4 - 6 as moderate pain; and 7 - 10 as severe pain.

    Time frame: End of Period (includes both Visits 6 and 11)

  3. Brief Pain Inventory-Short Form (BPI-sf) Score for Pain-Severity Domain at the End of Each Treatment Period (Week 6 of Each Treatment Period)

    The BPI-sf is a self-administered questionnaire developed to assess the severity of pain and the impact of pain on daily functions during a 24 hour period prior to evaluation. The BPI-sf consists of 5 questions: 4 items measure pain (0: no pain; 10: worst pain possible) at its "worst, "least", "average", and "now" (current pain) on an 11-point scale. Scores range from 0 - 40 with higher scores indicating greater pain severity. Another item, containing 7 sub-questions, evaluates the level of interference of pain on daily functioning (general activity, walking, work ability, mood, enjoyment of life, relations with other people, and sleep) on 11-point scales (0: does not interfere; 10: completely interferes). Scores range from 0 - 70 with higher scores indicating greater interference.

    Time frame: End of Period (includes both Visits 6 and 11)

  4. BPI-sf Score for Pain-Interference Domain at the End of Each Treatment Period (Week 6 of Each Treatment Period)

    The BPI-sf is a self-administered questionnaire developed to assess the severity of pain and the impact of pain on daily functions during a 24 hour period prior to evaluation. The BPI-sf consists of 5 questions: 4 items measure pain (0: no pain; 10: worst pain possible) at its "worst, "least", "average", and "now" (current pain) on an 11-point scale. Scores range from 0 - 40 with higher scores indicating greater pain severity. Another item, containing 7 sub-questions, evaluates the level of interference of pain on daily functioning (general activity, walking, work ability, mood, enjoyment of life, relations with other people, and sleep) on 11-point scales (0: does not interfere; 10: completely interferes). Scores range from 0 - 70 with higher scores indicating greater interference.

    Time frame: End of Period (includes both Visits 6 and 11)

  5. BPI-sf Score for Pain-Interference With Walking Ability at the End of Each Treatment Period (Week 6 of Each Treatment Period)

    The BPI-sf is a self-administered questionnaire developed to assess the severity of pain and the impact of pain on daily functions during a 24 hour period prior to evaluation. The BPI-sf consists of 5 questions: 4 items measure pain on an 11-point scale. Scores range from 0 - 40 with higher scores indicating greater pain severity. Another item, containing 7 sub-questions, evaluates the level of interference of pain on daily functioning (general activity, walking, work ability, mood, enjoyment of life, relations with other people, and sleep) on 11-point scales (0: does not interfere; 10: completely interferes). Scores range from 0 - 70 with higher scores indicating greater interference. The sub-score pain interference with walking ability was evaluated, as it was considered to be the most relevant in the context of this study.

    Time frame: End of Period (includes both Visits 6 and 11)

  6. Daytime Total Activity Counts Per Day Measured by Actigraphy Over the Last 7 Days of Each Treatment Period (Week 6 of Each Treatment Period)

    Actigraphy data which measured steps and daytime activity during waking hours were assessed for the last 7 days at Baseline, Visit 6, and Visit 11. Activity counts are the units of motion. It is equal to the sum of peak accelerations each second during the epoch (60 seconds). Total activity counts per day is the sum of the activity counts for each epoch (60 seconds) during the "day" (non-sleep period). Actigraphy was performed with an accelerometer that was worn on the hip during the waking hours. It was programmed to record movements while the device was being worn.

    Time frame: End of Period (includes both Visits 6 and 11)

  7. Steps Per Day Measured by Actigraphy Over the Last 7 Days of Each Treatment Period (Week 6 of Each Treatment Period)

    Actigraphy data which measured steps and daytime activity during waking hours were assessed for the last 7 days at Baseline, Visit 6, and Visit 11. The participants were instructed to wear the device on their hip during the waking hours.

    Time frame: End of Period (includes both Visits 6 and 11)

  8. Walk 12 Questionnaire Over the Last 2 Weeks of Each Treatment Period (Week 6 of Each Treatment Period)

    The Walk-12 is a self-administered questionnaire that assesses the impact of the participant's diabetic neuropathy over the past 2 weeks on parameters associated with walking (12 questions) based on a 5-point scale (from not at all to extremely). The total score is the sum of scores from the 12 questions, which then gets transferred to a 0-100 scale with higher scores indicating greater impairment

    Time frame: End of Period (includes both Visits 6 and 11)

  9. Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QOL-DN) Total Quality of Life (TQOL) Score Measured Over the Last 2 Weeks of Each Treatment Period (Week 6 of Each Treatment Period)

    Norfolk QOL-DN is a 35-item participant-rated questionnaire used to assess impact of diabetic neuropathy on the quality of life of participants with diabetic neuropathy. All symptoms (1 - 7) are scored as either 1 or 0, indicating presence or absence of the symptom. With the exception of questions 31 and 32, the other items are scored according to the 5-point Likert Scale (0 - 4, "no problem" to "severe problem"). In question 31, "good", the middle item, is scored as 0, "very good" as -1, "excellent" as -2, "fair" as 1, and "poor" as 2. In question 32, "about the same", the middle item, is scored as 0, "somewhat better" as -1, "much better" as -2, "somewhat worse" as 1, and "much worse" as 2. TQOL score should be summed as follow: sum (Σ) (1 - 7, 8 - 35). The scales and subscales are calculated without weighting of any kind, and reported as the integer sum of the listed questionnaire items.

    Time frame: End of Period (includes both Visits 6 and 11)

  10. Norfolk QOL-DN Symptoms Domain Score Measured Over the Last 2 Weeks of Each Treatment Period (Week 6 of Each Treatment Period)

    Norfolk QOL-DN is a 35-item participant-rated questionnaire used to assess impact of diabetic neuropathy on the quality of life of participants with diabetic neuropathy. All symptoms (1 - 7) are scored as either 1 or 0, indicating presence or absence of the symptom. With the exception of questions 31 and 32, the other items are scored according to the 5-point Likert Scale (0 - 4, "no problem" to "severe problem"). In question 31, "good", the middle item, is scored as 0, "very good" as -1, "excellent" as -2, "fair" as 1, and "poor" as 2. In question 32, "about the same", the middle item, is scored as 0, "somewhat better" as -1, "much better" as -2, "somewhat worse" as 1, and "much worse" as 2. The symptoms domain score should be summed as follow: Σ(1 - 7, 9). The scales and subscales are calculated without weighting of any kind, and reported as the integer sum of the listed questionnaire items.

    Time frame: End of Period (includes both Visits 6 and 11)

  11. Norfolk QOL-DN Activities of Daily Living Domain Score Measured Over the Last 2 Weeks of Each Treatment Period (Week 6 of Each Treatment Period)

    Norfolk QOL-DN is a 35-item participant-rated questionnaire used to assess impact of diabetic neuropathy on the quality of life of participants with diabetic neuropathy. All symptoms (1 - 7) are scored as either 1 or 0, indicating presence or absence of the symptom. With the exception of questions 31 and 32, the other items are scored according to the 5-point Likert Scale (0 - 4, "no problem" to "severe problem"). In question 31, "good", the middle item, is scored as 0, "very good" as -1, "excellent" as -2, "fair" as 1, and "poor" as 2. In question 32, "about the same", the middle item, is scored as 0, "somewhat better" as -1, "much better" as -2, "somewhat worse" as 1, and "much worse" as 2. The activities of daily living domain score should be summed as follow: Σ(12, 22, 23, 25, 26). The scales and subscales are calculated without weighting of any kind, and reported as the integer sum of the listed questionnaire items.

    Time frame: End of Period (includes both Visits 6 and 11)

  12. Norfolk QOL-DN Physical Functioning / Large Fiber Domain Score Measured Over the Last 2 Weeks of Each Treatment Period (Week 6 of Each Treatment Period)

    Norfolk QOL-DN is a 35-item participant-rated questionnaire used to assess impact of diabetic neuropathy on the quality of life of participants with diabetic neuropathy. All symptoms (1 - 7) are scored as either 1 or 0, indicating presence or absence of the symptom. With the exception of questions 31 and 32, the other items are scored according to the 5-point Likert Scale (0 - 4, "no problem" to "severe problem"). In question 31, "good", the middle item, is scored as 0, "very good" as -1, "excellent" as -2, "fair" as 1, and "poor" as 2. In question 32, "about the same", the middle item, is scored as 0, "somewhat better" as -1, "much better" as -2, "somewhat worse" as 1, and "much worse" as 2. The physical functioning / large fiber domain score should be summed as follow: Σ(8, 11, 13 - 15, 24, 27 - 35). The scales and subscales are calculated without weighting of any kind, and reported as the integer sum of the listed questionnaire items.

    Time frame: End of Period (includes both Visits 6 and 11)

  13. Norfolk QOL-DN Small Fiber Domain Score Measured Over the Last 2 Weeks of Each Treatment Period (Week 6 of Each Treatment Period)

    Norfolk QOL-DN is a 35-item participant-rated questionnaire used to assess impact of diabetic neuropathy on the quality of life of participants with diabetic neuropathy. All symptoms (1 - 7) are scored as either 1 or 0, indicating presence or absence of the symptom. With the exception of questions 31 and 32, the other items are scored according to the 5-point Likert Scale (0 - 4, "no problem" to "severe problem"). In question 31, "good", the middle item, is scored as 0, "very good" as -1, "excellent" as -2, "fair" as 1, and "poor" as 2. In question 32, "about the same", the middle item, is scored as 0, "somewhat better" as -1, "much better" as -2, "somewhat worse" as 1, and "much worse" as 2. The small fiber domain score should be summed as follow: Σ(10, 16, 17, 18). The scales and subscales are calculated without weighting of any kind, and reported as the integer sum of the listed questionnaire items.

    Time frame: End of Period (includes both Visits 6 and 11)

  14. Norfolk QOL-DN Autonomic Domain Score Measured Over the Last 2 Weeks of Each Treatment Period (Week 6 of Each Treatment Period)

    Norfolk QOL-DN is a 35-item participant-rated questionnaire used to assess impact of diabetic neuropathy on the quality of life of participants with diabetic neuropathy. All symptoms (1 - 7) are scored as either 1 or 0, indicating presence or absence of the symptom. With the exception of questions 31 and 32, the other items are scored according to the 5-point Likert Scale (0 - 4, "no problem" to "severe problem"). In question 31, "good", the middle item, is scored as 0, "very good" as -1, "excellent" as -2, "fair" as 1, and "poor" as 2. In question 32, "about the same", the middle item, is scored as 0, "somewhat better" as -1, "much better" as -2, "somewhat worse" as 1, and "much worse" as 2. The autonomic domain score should be summed as follow: Σ(19, 20, 21). The scales and subscales are calculated without weighting of any kind, and reported as the integer sum of the listed questionnaire items.

    Time frame: End of Period (includes both Visits 6 and 11)

  15. Percentage of Participants With Patient Global Impression of Change (PGIC) Score From Baseline at the End of Period 1 (Week 6)

    The PGIC is a participant-rated instrument that measures the participant's assessment of change in his/her overall status on a scale ranging from 1 (very much improved) to 7 (very much worse). Original scores (OS; 7 different scores) and categorized scores (CS; 4 different scores) were provided. Categorized scores were very much improved (consisting of very much improved and much improved); any improvement (consisting of very much improved, much improved, and minimally improved); no change (consisting of no change); and any worsening (consisting of minimally worse, much worse, and very much worse). Due to the crossover design, PGIC was analyzed at the end of period 1 (V6).

    Time frame: End of Period 1 (V6)

  16. Mean Sleep Interference Rating Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)

    The daily sleep diary consists of an 11-point numeric rating scale with which the participant rates how painful DPN pain has interfered with their sleep during the past 24 hours. Zero indicates "does not interfere with sleep" and 10 indicates "completely interferes (unable to sleep due to pain)". Self-assessment was performed daily in the evening before bedtime on a telephone via IVRS (time window for completion between 6.00 pm to midnight) after completion of the daily pain diary.

    Time frame: End of Period (includes both Visits 6 and 11)

  17. Hospital Anxiety and Depression Scale - Anxiety (HADS-A) Total Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)

    The Hospital Anxiety and Depression Scale (HADS) is a 14-item self-administered questionnaire that consists of 2 scales, one measuring anxiety (HADS-A), and the other measuring depression (HADS-D). Each subscale consists of 7 statements and the participant responds as to how each item applies to him/her over the past week on 4-point response scale. Separate scores are calculated for anxiety and depression and a score (ranging from 0 to 21) is obtained for each subscale. The higher the score, the more severe the anxiety or depression.

    Time frame: End of Period (includes both Visits 6 and 11)

  18. Hospital Anxiety and Depression Scale - Depression (HADS-D) Total Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)

    The HADS is a 14-item self-administered questionnaire that consists of 2 scales, one measuring anxiety (HADS-A), and the other measuring depression (HADS-D). Each subscale consists of 7 statements and the participant responds as to how each item applies to him/her over the past week on 4-point response scale. Separate scores are calculated for anxiety and depression and a score (ranging from 0 to 21) is obtained for each subscale. The higher the score, the more severe the anxiety or depression.

    Time frame: End of Period (includes both Visits 6 and 11)

  19. Euro QoL-5 Dimensions (EQ-5D) - Health State Profile Utility Scores at the End of Each Treatment Period (Week 6 of Each Treatment Period)

    The EQ-5D describes participant's health status based on 5 attributes producing an 5 digit index score. The 5 dimensions are: mobility, self-care, usual activities, pain / discomfort, and anxiety / depression. Dolan 1997 advised how to transfer this index score to a single score for clinical trials, a revised single index was published in 2001. The index uses general population weighted estimates for various health states. In general, the range of the single index tends to vary between 0 = death and 1 = perfect health and there are some states that have been rated by the general population to be worse than death which may result in numbers below 0.

    Time frame: End of Period (includes both Visits 6 and 11)

07

Results

Posted Nov 18, 2014

Participant flow

411 participants were screened, of whom 206 were withdrawn before randomization. 205 were randomized, of whom 2 discontinued before being treated. Participants were randomized at 36 centers in 4 countries: US (25), Sweden (4), South Africa (4), and Czech Republic (3). 11 centers received study drug but did not randomize participants.

Period 1
Participant flow — Period 1
MilestonePregabalin/PlaceboPlacebo/Pregablin
Started101102
Completed8999
Not completed123
Withdrew: Adverse event (ae) related to study drug61
Withdrew: Ae not related to study drug10
Withdrew: Withdrawal by subject31
Withdrew: Lost to follow-up10
Withdrew: Reason not specified11
Washout
Participant flow — Washout
MilestonePregabalin/PlaceboPlacebo/Pregablin
Started8999
Completed8697
Not completed32
Withdrew: Ae not related to study drug20
Withdrew: Withdrawal by subject10
Withdrew: Lost to follow-up01
Withdrew: Reason not specified01
Period 2
Participant flow — Period 2
MilestonePregabalin/PlaceboPlacebo/Pregablin
Started8697
Completed7787
Not completed910
Withdrew: Death01
Withdrew: Ae related to study drug01
Withdrew: Ae not related to study drug41
Withdrew: Lack of efficacy10
Withdrew: Withdrawal by subject34
Withdrew: Lost to follow-up11
Withdrew: Reason not specified02
Follow-up
Participant flow — Follow-up
MilestonePregabalin/PlaceboPlacebo/Pregablin
Started7787
Completed7786
Not completed01
Withdrew: Ae not related to study drug01

Outcome measures

PrimaryAverage Diabetic Peripheral Neuropathy (DPN) Pain Based on a Numeric Rating Scale (NRS) Over the Last 7 Days of Each Treatment Period (Week 6 of Each Treatment Period)

The daily pain diary consisted of an 11-point numeric scale ranging from 0 ("no pain") to 10 ("worst possible pain"). Participants described their pain during the past 24 hours by having chosen the appropriate number between 0 and 10. Self-assessment was performed daily each evening before bedtime (6.00 pm to midnight) on the telephone via Interactive Voice Recognition System (IVRS). The endpoint mean pain score was defined as the mean of the last 7 daily diary pain ratings while taking study medication in each treatment period - Period 1 and Period 2, respectively. A rating of 1 - 3 was considered as mild pain; 4 - 6 as moderate pain; and 7 - 10 as severe pain.

Time frame:
End of Period (includes both Visits 6 and 11)
Reported as:
Least squares mean · units on a scale
Average Diabetic Peripheral Neuropathy (DPN) Pain Based on a Numeric Rating Scale (NRS) Over the Last 7 Days of Each Treatment Period (Week 6 of Each Treatment Period)
units on a scalePregabalinPlacebo
Average Diabetic Peripheral Neuropathy (DPN) Pain Based on a Numeric Rating Scale (NRS) Over the Last 7 Days of Each Treatment Period (Week 6 of Each Treatment Period)4.73 ± 0.144.96 ± 0.14
Statistical analysis
  • Pregabalin vs Placebo · Linear mixed effects model · p = 0.0659 (Primary analysis was two-sided and performed at the 0.05 significance level. The study was considered positive only if both co-primary endpoints had p-values that were less than 0.05, hence there was no need for multiplicity adjustment.) · Mean difference (final values): -0.22 · 95% CI -0.46 to 0.01
Post-hocAverage Weekly DPN Pain Based on a NRS (Baseline, 6 Weeks in Period 1, 2 Weeks Washout and 6 Weeks in Period 2)

The daily pain diary consisted of an 11-point numeric scale ranging from 0 ("no pain") to 10 ("worst possible pain"). Participants described their pain during the past 24 hours by having chosen the appropriate number between 0 and 10. Self-assessment was performed daily each evening before bedtime (6.00 pm to midnight) on the telephone via IVRS. The longitudinal mean weekly DPN pain scores were defined as the mean of 7 daily diary pain ratings. A rating of 1 - 3 was considered as mild pain; 4 - 6 as moderate pain; and 7 - 10 as severe pain.

Time frame:
Baseline, 6 weeks in Period 1, 2 weeks washout and 6 weeks in Period 2
Reported as:
Mean · units on a scale
Average Weekly DPN Pain Based on a NRS (Baseline, 6 Weeks in Period 1, 2 Weeks Washout and 6 Weeks in Period 2)
units on a scalePregabalinPlacebo
V6 (N: 101, 102)4.66 ± 1.775.29 ± 1.93
V11 (N: 97, 84)4.57 ± 2.224.38 ± 2.17
Statistical analysis
  • Pregabalin vs Placebo · Repeated measure mixed effects model · p = 0.0242 (Primary analysis was two-sided and performed at the 0.05 significance level. Unstructured covariance structure was used to estimate the within-participant errors.) · Mean difference (final values): -0.291 · 95% CI -0.543 to -0.038The Kenward-Roger method was used to estimate denominator degrees of freedom.
PrimaryDPN Pain on Walking Based on a 11-point NRS of Each Treatment Period (Week 6 of Each Treatment Period)

The post-test DPN pain on walking NRS consisted of an 11-point numeric scale ranging from 0 ("no pain") to 10 ("worst possible pain"). Participants described their DPN pain in their legs and/or feet while walking during the 50-foot walk test by choosing the appropriate number between 0 and 10. The post-test DPN pain on walking NRS was completed by the participant using paper-pen administration immediately after completing the 50-foot walk test at the end of each treatment period - Period 1 and Period 2, respectively. A rating of 1 - 3 was considered as mild pain; 4 - 6 as moderate pain; and 7 - 10 as severe pain.

Time frame:
End of Period (includes both Visits 6 and 11)
Reported as:
Least squares mean · units on a scale
DPN Pain on Walking Based on a 11-point NRS of Each Treatment Period (Week 6 of Each Treatment Period)
units on a scalePregabalinPlacebo
DPN Pain on Walking Based on a 11-point NRS of Each Treatment Period (Week 6 of Each Treatment Period)4.28 ± 0.154.41 ± 0.15
Statistical analysis
  • Pregabalin vs Placebo · Mixed-Effect Model Repeated Measures · p = 0.4120 (Primary analysis was two-sided and performed at the 0.05 significance level. The study was considered positive only if both co-primary endpoints have p-values that are less than 0.05, hence there was no need for multiplicity adjustment.) · Mean difference (final values): -0.13 · 95% CI -0.44 to 0.18Satterthwaite's approximation was used to estimate denominator degrees of freedom.
SecondaryPercentage of Participants Achieving 30% Reduction in Mean DPN Pain Score From Baseline at the End of Each Treatment Period (Week 6 of Each Treatment Period)

The daily pain diary consisted of an 11-point numeric scale ranging from 0 ("no pain") to 10 ("worst possible pain"). Participants described their pain during the past 24 hours by having chosen the appropriate number between 0 and 10. Self-assessment was performed daily each evening before bedtime (6.00 pm to midnight) on the telephone via IVRS. The endpoint mean pain score was defined as the mean of the last 7 daily diary pain ratings while taking study medication in each treatment period - Period 1 and Period 2, respectively. A rating of 1 - 3 was considered as mild pain; 4 - 6 as moderate pain; and 7 - 10 as severe pain.

Time frame:
End of Period (includes both Visits 6 and 11)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving 30% Reduction in Mean DPN Pain Score From Baseline at the End of Each Treatment Period (Week 6 of Each Treatment Period)
percentage of participantsPregabalinPlacebo
V6 (N: 101, 102)38.624.5
V11 (N: 97, 84)46.447.6
Statistical analysis
  • Pregabalin vs Placebo · Generalized linear mixed model · p = 0.0847 (Secondary analysis was two-sided and performed at the 0.05 significance level. No corrections to alpha to control for potential inflation of Type I error resulting from multiple comparisons were made.) · Odds ratio (or): 1.55 · 95% CI 0.94 to 2.55
SecondaryPercentage of Participants Achieving 50% Reduction in Mean DPN Pain Score From Baseline at the End of Each Treatment Period (Week 6 of Each Treatment Period)

The daily pain diary consisted of an 11-point numeric scale ranging from 0 ("no pain") to 10 ("worst possible pain"). Participants described their pain during the past 24 hours by having chosen the appropriate number between 0 and 10. Self-assessment was performed daily each evening before bedtime (6.00 pm to midnight) on the telephone via IVRS. The endpoint mean pain score was defined as the mean of the last 7 daily diary pain ratings while taking study medication in each treatment period - Period 1 and Period 2, respectively. A rating of 1 - 3 was considered as mild pain; 4 - 6 as moderate pain; and 7 - 10 as severe pain.

Time frame:
End of Period (includes both Visits 6 and 11)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving 50% Reduction in Mean DPN Pain Score From Baseline at the End of Each Treatment Period (Week 6 of Each Treatment Period)
percentage of participantsPregabalinPlacebo
V6 (N: 101, 102)23.813.7
V11 (N: 97, 84)27.832.1
Statistical analysis
  • Pregabalin vs Placebo · Generalized linear mixed model · p = 0.2459 (Secondary analysis was two-sided and performed at the 0.05 significance level. No corrections to alpha to control for potential inflation of Type I error resulting from multiple comparisons were made.) · Odds ratio (or): 1.38 · 95% CI 0.80 to 2.39
SecondaryBrief Pain Inventory-Short Form (BPI-sf) Score for Pain-Severity Domain at the End of Each Treatment Period (Week 6 of Each Treatment Period)

The BPI-sf is a self-administered questionnaire developed to assess the severity of pain and the impact of pain on daily functions during a 24 hour period prior to evaluation. The BPI-sf consists of 5 questions: 4 items measure pain (0: no pain; 10: worst pain possible) at its "worst, "least", "average", and "now" (current pain) on an 11-point scale. Scores range from 0 - 40 with higher scores indicating greater pain severity. Another item, containing 7 sub-questions, evaluates the level of interference of pain on daily functioning (general activity, walking, work ability, mood, enjoyment of life, relations with other people, and sleep) on 11-point scales (0: does not interfere; 10: completely interferes). Scores range from 0 - 70 with higher scores indicating greater interference.

Time frame:
End of Period (includes both Visits 6 and 11)
Reported as:
Least squares mean · units on a scale
Brief Pain Inventory-Short Form (BPI-sf) Score for Pain-Severity Domain at the End of Each Treatment Period (Week 6 of Each Treatment Period)
units on a scalePregabalinPlacebo
Brief Pain Inventory-Short Form (BPI-sf) Score for Pain-Severity Domain at the End of Each Treatment Period (Week 6 of Each Treatment Period)16.76 ± 0.5617.56 ± 0.75
Statistical analysis
  • Pregabalin vs Placebo · Linear mixed effects model · p = 0.0889 (Secondary analysis was two-sided and performed at the 0.05 significance level. No corrections to alpha to control for potential inflation of Type I error resulting from multiple comparisons were made.) · Mean difference (final values): -0.80 · 95% CI -1.71 to 0.12
SecondaryBPI-sf Score for Pain-Interference Domain at the End of Each Treatment Period (Week 6 of Each Treatment Period)

The BPI-sf is a self-administered questionnaire developed to assess the severity of pain and the impact of pain on daily functions during a 24 hour period prior to evaluation. The BPI-sf consists of 5 questions: 4 items measure pain (0: no pain; 10: worst pain possible) at its "worst, "least", "average", and "now" (current pain) on an 11-point scale. Scores range from 0 - 40 with higher scores indicating greater pain severity. Another item, containing 7 sub-questions, evaluates the level of interference of pain on daily functioning (general activity, walking, work ability, mood, enjoyment of life, relations with other people, and sleep) on 11-point scales (0: does not interfere; 10: completely interferes). Scores range from 0 - 70 with higher scores indicating greater interference.

Time frame:
End of Period (includes both Visits 6 and 11)
Reported as:
Least squares mean · units on a scale
BPI-sf Score for Pain-Interference Domain at the End of Each Treatment Period (Week 6 of Each Treatment Period)
units on a scalePregabalinPlacebo
BPI-sf Score for Pain-Interference Domain at the End of Each Treatment Period (Week 6 of Each Treatment Period)22.58 ± 0.9623.75 ± 0.98
Statistical analysis
  • Pregabalin vs Placebo · Linear mixed effects model · p = 0.1781 (Secondary analysis was two-sided and performed at the 0.05 significance level. No corrections to alpha to control for potential inflation of Type I error resulting from multiple comparisons were made.) · Mean difference (final values): -1.16 · 95% CI -2.86 to 0.53
SecondaryBPI-sf Score for Pain-Interference With Walking Ability at the End of Each Treatment Period (Week 6 of Each Treatment Period)

The BPI-sf is a self-administered questionnaire developed to assess the severity of pain and the impact of pain on daily functions during a 24 hour period prior to evaluation. The BPI-sf consists of 5 questions: 4 items measure pain on an 11-point scale. Scores range from 0 - 40 with higher scores indicating greater pain severity. Another item, containing 7 sub-questions, evaluates the level of interference of pain on daily functioning (general activity, walking, work ability, mood, enjoyment of life, relations with other people, and sleep) on 11-point scales (0: does not interfere; 10: completely interferes). Scores range from 0 - 70 with higher scores indicating greater interference. The sub-score pain interference with walking ability was evaluated, as it was considered to be the most relevant in the context of this study.

Time frame:
End of Period (includes both Visits 6 and 11)
Reported as:
Least squares mean · units on a scale
BPI-sf Score for Pain-Interference With Walking Ability at the End of Each Treatment Period (Week 6 of Each Treatment Period)
units on a scalePregabalinPlacebo
BPI-sf Score for Pain-Interference With Walking Ability at the End of Each Treatment Period (Week 6 of Each Treatment Period)3.75 ± 0.173.93 ± 0.18
Statistical analysis
  • Pregabalin vs Placebo · Linear mixed effects model · p = 0.2719 (Secondary analysis was two-sided and performed at the 0.05 significance level. No corrections to alpha to control for potential inflation of Type I error resulting from multiple comparisons were made.) · Mean difference (final values): -0.19 · 95% CI -0.53 to 0.15
SecondaryDaytime Total Activity Counts Per Day Measured by Actigraphy Over the Last 7 Days of Each Treatment Period (Week 6 of Each Treatment Period)

Actigraphy data which measured steps and daytime activity during waking hours were assessed for the last 7 days at Baseline, Visit 6, and Visit 11. Activity counts are the units of motion. It is equal to the sum of peak accelerations each second during the epoch (60 seconds). Total activity counts per day is the sum of the activity counts for each epoch (60 seconds) during the "day" (non-sleep period). Actigraphy was performed with an accelerometer that was worn on the hip during the waking hours. It was programmed to record movements while the device was being worn.

Time frame:
End of Period (includes both Visits 6 and 11)
Reported as:
Least squares mean · counts
Daytime Total Activity Counts Per Day Measured by Actigraphy Over the Last 7 Days of Each Treatment Period (Week 6 of Each Treatment Period)
countsPregabalinPlacebo
Daytime Total Activity Counts Per Day Measured by Actigraphy Over the Last 7 Days of Each Treatment Period (Week 6 of Each Treatment Period)64703.14 ± 4005.0064139.75 ± 4057.89
Statistical analysis
  • Pregabalin vs Placebo · Linear mixed effects model · p = 0.8909 (Secondary analysis was two-sided and performed at the 0.05 significance level. No corrections to alpha to control for potential inflation of Type I error resulting from multiple comparisons were made.) · Mean difference (final values): 563.39 · 95% CI -7549.82 to 8676.60
SecondarySteps Per Day Measured by Actigraphy Over the Last 7 Days of Each Treatment Period (Week 6 of Each Treatment Period)

Actigraphy data which measured steps and daytime activity during waking hours were assessed for the last 7 days at Baseline, Visit 6, and Visit 11. The participants were instructed to wear the device on their hip during the waking hours.

Time frame:
End of Period (includes both Visits 6 and 11)
Reported as:
Least squares mean · steps
Steps Per Day Measured by Actigraphy Over the Last 7 Days of Each Treatment Period (Week 6 of Each Treatment Period)
stepsPregabalinPlacebo
Steps Per Day Measured by Actigraphy Over the Last 7 Days of Each Treatment Period (Week 6 of Each Treatment Period)3785.65 ± 201.173788.28 ± 203.05
Statistical analysis
  • Pregabalin vs Placebo · Linear mixed effects model · p = 0.9899 (Secondary analysis was two-sided and performed at the 0.05 significance level. No corrections to alpha to control for potential inflation of Type I error resulting from multiple comparisons were made.) · Mean difference (final values): -2.63 · 95% CI -411.26 to 406.01
SecondaryWalk 12 Questionnaire Over the Last 2 Weeks of Each Treatment Period (Week 6 of Each Treatment Period)

The Walk-12 is a self-administered questionnaire that assesses the impact of the participant's diabetic neuropathy over the past 2 weeks on parameters associated with walking (12 questions) based on a 5-point scale (from not at all to extremely). The total score is the sum of scores from the 12 questions, which then gets transferred to a 0-100 scale with higher scores indicating greater impairment

Time frame:
End of Period (includes both Visits 6 and 11)
Reported as:
Least squares mean · units on a scale
Walk 12 Questionnaire Over the Last 2 Weeks of Each Treatment Period (Week 6 of Each Treatment Period)
units on a scalePregabalinPlacebo
Walk 12 Questionnaire Over the Last 2 Weeks of Each Treatment Period (Week 6 of Each Treatment Period)35.72 ± 1.4437.08 ± 1.46
Statistical analysis
  • Pregabalin vs Placebo · Linear mixed effects model · p = 0.2854 (Secondary analysis was two-sided and performed at the 0.05 significance level. No corrections to alpha to control for potential inflation of Type I error resulting from multiple comparisons were made.) · Mean difference (final values): -1.37 · 95% CI -3.88 to 1.15
SecondaryNorfolk Quality of Life-Diabetic Neuropathy (Norfolk QOL-DN) Total Quality of Life (TQOL) Score Measured Over the Last 2 Weeks of Each Treatment Period (Week 6 of Each Treatment Period)

Norfolk QOL-DN is a 35-item participant-rated questionnaire used to assess impact of diabetic neuropathy on the quality of life of participants with diabetic neuropathy. All symptoms (1 - 7) are scored as either 1 or 0, indicating presence or absence of the symptom. With the exception of questions 31 and 32, the other items are scored according to the 5-point Likert Scale (0 - 4, "no problem" to "severe problem"). In question 31, "good", the middle item, is scored as 0, "very good" as -1, "excellent" as -2, "fair" as 1, and "poor" as 2. In question 32, "about the same", the middle item, is scored as 0, "somewhat better" as -1, "much better" as -2, "somewhat worse" as 1, and "much worse" as 2. TQOL score should be summed as follow: sum (Σ) (1 - 7, 8 - 35). The scales and subscales are calculated without weighting of any kind, and reported as the integer sum of the listed questionnaire items.

Time frame:
End of Period (includes both Visits 6 and 11)
Reported as:
Least squares mean · units on a scale
Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QOL-DN) Total Quality of Life (TQOL) Score Measured Over the Last 2 Weeks of Each Treatment Period (Week 6 of Each Treatment Period)
units on a scalePregabalinPlacebo
Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QOL-DN) Total Quality of Life (TQOL) Score Measured Over the Last 2 Weeks of Each Treatment Period (Week 6 of Each Treatment Period)29.31 ± 1.1730.77 ± 1.19
Statistical analysis
  • Pregabalin vs Placebo · Linear mixed effects model · p = 0.1805 (Secondary analysis was two-sided and performed at the 0.05 significance level. No corrections to alpha to control for potential inflation of Type I error resulting from multiple comparisons were made.) · Mean difference (final values): -1.46 · 95% CI -3.60 to 0.68
SecondaryNorfolk QOL-DN Symptoms Domain Score Measured Over the Last 2 Weeks of Each Treatment Period (Week 6 of Each Treatment Period)

Norfolk QOL-DN is a 35-item participant-rated questionnaire used to assess impact of diabetic neuropathy on the quality of life of participants with diabetic neuropathy. All symptoms (1 - 7) are scored as either 1 or 0, indicating presence or absence of the symptom. With the exception of questions 31 and 32, the other items are scored according to the 5-point Likert Scale (0 - 4, "no problem" to "severe problem"). In question 31, "good", the middle item, is scored as 0, "very good" as -1, "excellent" as -2, "fair" as 1, and "poor" as 2. In question 32, "about the same", the middle item, is scored as 0, "somewhat better" as -1, "much better" as -2, "somewhat worse" as 1, and "much worse" as 2. The symptoms domain score should be summed as follow: Σ(1 - 7, 9). The scales and subscales are calculated without weighting of any kind, and reported as the integer sum of the listed questionnaire items.

Time frame:
End of Period (includes both Visits 6 and 11)
Reported as:
Least squares mean · units on a scale
Norfolk QOL-DN Symptoms Domain Score Measured Over the Last 2 Weeks of Each Treatment Period (Week 6 of Each Treatment Period)
units on a scalePregabalinPlacebo
Norfolk QOL-DN Symptoms Domain Score Measured Over the Last 2 Weeks of Each Treatment Period (Week 6 of Each Treatment Period)7.65 ± 0.327.99 ± 0.33
Statistical analysis
  • Pregabalin vs Placebo · Linear mixed effects model · p = 0.3028 (Secondary analysis was two-sided and performed at the 0.05 significance level. No corrections to alpha to control for potential inflation of Type I error resulting from multiple comparisons were made.) · Mean difference (final values): -0.34 · 95% CI -0.99 to 0.31
SecondaryNorfolk QOL-DN Activities of Daily Living Domain Score Measured Over the Last 2 Weeks of Each Treatment Period (Week 6 of Each Treatment Period)

Norfolk QOL-DN is a 35-item participant-rated questionnaire used to assess impact of diabetic neuropathy on the quality of life of participants with diabetic neuropathy. All symptoms (1 - 7) are scored as either 1 or 0, indicating presence or absence of the symptom. With the exception of questions 31 and 32, the other items are scored according to the 5-point Likert Scale (0 - 4, "no problem" to "severe problem"). In question 31, "good", the middle item, is scored as 0, "very good" as -1, "excellent" as -2, "fair" as 1, and "poor" as 2. In question 32, "about the same", the middle item, is scored as 0, "somewhat better" as -1, "much better" as -2, "somewhat worse" as 1, and "much worse" as 2. The activities of daily living domain score should be summed as follow: Σ(12, 22, 23, 25, 26). The scales and subscales are calculated without weighting of any kind, and reported as the integer sum of the listed questionnaire items.

Time frame:
End of Period (includes both Visits 6 and 11)
Reported as:
Least squares mean · units on a scale
Norfolk QOL-DN Activities of Daily Living Domain Score Measured Over the Last 2 Weeks of Each Treatment Period (Week 6 of Each Treatment Period)
units on a scalePregabalinPlacebo
Norfolk QOL-DN Activities of Daily Living Domain Score Measured Over the Last 2 Weeks of Each Treatment Period (Week 6 of Each Treatment Period)2.36 ± 0.192.42 ± 0.20
Statistical analysis
  • Pregabalin vs Placebo · Linear mixed effects model · p = 0.7542 (Secondary analysis was two-sided and performed at the 0.05 significance level. No corrections to alpha to control for potential inflation of Type I error resulting from multiple comparisons were made.) · Mean difference (final values): -0.06 · 95% CI -0.41 to 0.30
SecondaryNorfolk QOL-DN Physical Functioning / Large Fiber Domain Score Measured Over the Last 2 Weeks of Each Treatment Period (Week 6 of Each Treatment Period)

Norfolk QOL-DN is a 35-item participant-rated questionnaire used to assess impact of diabetic neuropathy on the quality of life of participants with diabetic neuropathy. All symptoms (1 - 7) are scored as either 1 or 0, indicating presence or absence of the symptom. With the exception of questions 31 and 32, the other items are scored according to the 5-point Likert Scale (0 - 4, "no problem" to "severe problem"). In question 31, "good", the middle item, is scored as 0, "very good" as -1, "excellent" as -2, "fair" as 1, and "poor" as 2. In question 32, "about the same", the middle item, is scored as 0, "somewhat better" as -1, "much better" as -2, "somewhat worse" as 1, and "much worse" as 2. The physical functioning / large fiber domain score should be summed as follow: Σ(8, 11, 13 - 15, 24, 27 - 35). The scales and subscales are calculated without weighting of any kind, and reported as the integer sum of the listed questionnaire items.

Time frame:
End of Period (includes both Visits 6 and 11)
Reported as:
Least squares mean · units on a scale
Norfolk QOL-DN Physical Functioning / Large Fiber Domain Score Measured Over the Last 2 Weeks of Each Treatment Period (Week 6 of Each Treatment Period)
units on a scalePregabalinPlacebo
Norfolk QOL-DN Physical Functioning / Large Fiber Domain Score Measured Over the Last 2 Weeks of Each Treatment Period (Week 6 of Each Treatment Period)15.51 ± 0.7316.78 ± 0.75
Statistical analysis
  • Pregabalin vs Placebo · Linear mixed effects model · p = 0.0634 (Secondary analysis was two-sided and performed at the 0.05 significance level. No corrections to alpha to control for potential inflation of Type I error resulting from multiple comparisons were made.) · Mean difference (final values): -1.27 · 95% CI -2.62 to 0.07
SecondaryNorfolk QOL-DN Small Fiber Domain Score Measured Over the Last 2 Weeks of Each Treatment Period (Week 6 of Each Treatment Period)

Norfolk QOL-DN is a 35-item participant-rated questionnaire used to assess impact of diabetic neuropathy on the quality of life of participants with diabetic neuropathy. All symptoms (1 - 7) are scored as either 1 or 0, indicating presence or absence of the symptom. With the exception of questions 31 and 32, the other items are scored according to the 5-point Likert Scale (0 - 4, "no problem" to "severe problem"). In question 31, "good", the middle item, is scored as 0, "very good" as -1, "excellent" as -2, "fair" as 1, and "poor" as 2. In question 32, "about the same", the middle item, is scored as 0, "somewhat better" as -1, "much better" as -2, "somewhat worse" as 1, and "much worse" as 2. The small fiber domain score should be summed as follow: Σ(10, 16, 17, 18). The scales and subscales are calculated without weighting of any kind, and reported as the integer sum of the listed questionnaire items.

Time frame:
End of Period (includes both Visits 6 and 11)
Reported as:
Least squares mean · units on a scale
Norfolk QOL-DN Small Fiber Domain Score Measured Over the Last 2 Weeks of Each Treatment Period (Week 6 of Each Treatment Period)
units on a scalePregabalinPlacebo
Norfolk QOL-DN Small Fiber Domain Score Measured Over the Last 2 Weeks of Each Treatment Period (Week 6 of Each Treatment Period)2.77 ± 0.172.53 ± 0.17
Statistical analysis
  • Pregabalin vs Placebo · Linear mixed effects model · p = 0.1985 (Secondary analysis was two-sided and performed at the 0.05 significance level. No corrections to alpha to control for potential inflation of Type I error resulting from multiple comparisons were made.) · Mean difference (final values): 0.24 · 95% CI -0.13 to 0.62
SecondaryNorfolk QOL-DN Autonomic Domain Score Measured Over the Last 2 Weeks of Each Treatment Period (Week 6 of Each Treatment Period)

Norfolk QOL-DN is a 35-item participant-rated questionnaire used to assess impact of diabetic neuropathy on the quality of life of participants with diabetic neuropathy. All symptoms (1 - 7) are scored as either 1 or 0, indicating presence or absence of the symptom. With the exception of questions 31 and 32, the other items are scored according to the 5-point Likert Scale (0 - 4, "no problem" to "severe problem"). In question 31, "good", the middle item, is scored as 0, "very good" as -1, "excellent" as -2, "fair" as 1, and "poor" as 2. In question 32, "about the same", the middle item, is scored as 0, "somewhat better" as -1, "much better" as -2, "somewhat worse" as 1, and "much worse" as 2. The autonomic domain score should be summed as follow: Σ(19, 20, 21). The scales and subscales are calculated without weighting of any kind, and reported as the integer sum of the listed questionnaire items.

Time frame:
End of Period (includes both Visits 6 and 11)
Reported as:
Least squares mean · units on a scale
Norfolk QOL-DN Autonomic Domain Score Measured Over the Last 2 Weeks of Each Treatment Period (Week 6 of Each Treatment Period)
units on a scalePregabalinPlacebo
Norfolk QOL-DN Autonomic Domain Score Measured Over the Last 2 Weeks of Each Treatment Period (Week 6 of Each Treatment Period)1.07 ± 0.101.08 ± 0.10
Statistical analysis
  • Pregabalin vs Placebo · Linear mixed effects model · p = 0.9686 (Secondary analysis was two-sided and performed at the 0.05 significance level. No corrections to alpha to control for potential inflation of Type I error resulting from multiple comparisons were made.) · Mean difference (final values): -0.00 · 95% CI -0.21 to 0.20
SecondaryPercentage of Participants With Patient Global Impression of Change (PGIC) Score From Baseline at the End of Period 1 (Week 6)

The PGIC is a participant-rated instrument that measures the participant's assessment of change in his/her overall status on a scale ranging from 1 (very much improved) to 7 (very much worse). Original scores (OS; 7 different scores) and categorized scores (CS; 4 different scores) were provided. Categorized scores were very much improved (consisting of very much improved and much improved); any improvement (consisting of very much improved, much improved, and minimally improved); no change (consisting of no change); and any worsening (consisting of minimally worse, much worse, and very much worse). Due to the crossover design, PGIC was analyzed at the end of period 1 (V6).

Time frame:
End of Period 1 (V6)
Reported as:
Number · percentage of participants
Percentage of Participants With Patient Global Impression of Change (PGIC) Score From Baseline at the End of Period 1 (Week 6)
percentage of participantsPregabalinPlacebo
OS: Very much improved11.25.9
OS: Much improved39.825.5
OS: Minimally improved30.627.5
OS: No change13.333.3
OS: Minimally worse2.05.9
OS: Much worse2.01.0
OS: Very much worse1.01.0
CS: Very much improved51.031.4
CS: Any improvement81.658.8
CS: No change13.333.3
CS: Any worsening5.17.8
Statistical analysis
  • Pregabalin vs Placebo · Cochran-Mantel-Haenszel · p = 0.0020 · Odds ratio (or): 2.5400 · 95% CI 1.30 to 4.95
SecondaryMean Sleep Interference Rating Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)

The daily sleep diary consists of an 11-point numeric rating scale with which the participant rates how painful DPN pain has interfered with their sleep during the past 24 hours. Zero indicates "does not interfere with sleep" and 10 indicates "completely interferes (unable to sleep due to pain)". Self-assessment was performed daily in the evening before bedtime on a telephone via IVRS (time window for completion between 6.00 pm to midnight) after completion of the daily pain diary.

Time frame:
End of Period (includes both Visits 6 and 11)
Reported as:
Least squares mean · units on a scale
Mean Sleep Interference Rating Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)
units on a scalePregabalinPlacebo
Mean Sleep Interference Rating Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)3.66 ± 0.124.05 ± 0.13
Statistical analysis
  • Pregabalin vs Placebo · Linear mixed effects model · p = 0.0105 (Secondary analysis was two-sided and performed at the 0.05 significance level. No corrections to alpha to control for potential inflation of Type I error resulting from multiple comparisons were made.) · Mean difference (final values): -0.38 · 95% CI -0.68 to -0.09
SecondaryHospital Anxiety and Depression Scale - Anxiety (HADS-A) Total Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)

The Hospital Anxiety and Depression Scale (HADS) is a 14-item self-administered questionnaire that consists of 2 scales, one measuring anxiety (HADS-A), and the other measuring depression (HADS-D). Each subscale consists of 7 statements and the participant responds as to how each item applies to him/her over the past week on 4-point response scale. Separate scores are calculated for anxiety and depression and a score (ranging from 0 to 21) is obtained for each subscale. The higher the score, the more severe the anxiety or depression.

Time frame:
End of Period (includes both Visits 6 and 11)
Reported as:
Least squares mean · units on a scale
Hospital Anxiety and Depression Scale - Anxiety (HADS-A) Total Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)
units on a scalePregabalinPlacebo
Hospital Anxiety and Depression Scale - Anxiety (HADS-A) Total Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)4.65 ± 0.194.92 ± 0.20
Statistical analysis
  • Pregabalin vs Placebo · Linear mixed effects model · p = 0.1178 (Secondary analysis was two-sided and performed at the 0.05 significance level. No corrections to alpha to control for potential inflation of Type I error resulting from multiple comparisons were made.) · Mean difference (final values): -0.28 · 95% CI -0.63 to 0.07
SecondaryHospital Anxiety and Depression Scale - Depression (HADS-D) Total Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)

The HADS is a 14-item self-administered questionnaire that consists of 2 scales, one measuring anxiety (HADS-A), and the other measuring depression (HADS-D). Each subscale consists of 7 statements and the participant responds as to how each item applies to him/her over the past week on 4-point response scale. Separate scores are calculated for anxiety and depression and a score (ranging from 0 to 21) is obtained for each subscale. The higher the score, the more severe the anxiety or depression.

Time frame:
End of Period (includes both Visits 6 and 11)
Reported as:
Least squares mean · units on a scale
Hospital Anxiety and Depression Scale - Depression (HADS-D) Total Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)
units on a scalePregabalinPlacebo
Hospital Anxiety and Depression Scale - Depression (HADS-D) Total Score at the End of Each Treatment Period (Week 6 of Each Treatment Period)3.73 ± 0.203.97 ± 0.20
Statistical analysis
  • Pregabalin vs Placebo · Linear mixed effects model · p = 0.1990 (Secondary analysis was two-sided and performed at the 0.05 significance level. No corrections to alpha to control for potential inflation of Type I error resulting from multiple comparisons were made.) · Mean difference (final values): -0.24 · 95% CI -0.60 to 0.13
SecondaryEuro QoL-5 Dimensions (EQ-5D) - Health State Profile Utility Scores at the End of Each Treatment Period (Week 6 of Each Treatment Period)

The EQ-5D describes participant's health status based on 5 attributes producing an 5 digit index score. The 5 dimensions are: mobility, self-care, usual activities, pain / discomfort, and anxiety / depression. Dolan 1997 advised how to transfer this index score to a single score for clinical trials, a revised single index was published in 2001. The index uses general population weighted estimates for various health states. In general, the range of the single index tends to vary between 0 = death and 1 = perfect health and there are some states that have been rated by the general population to be worse than death which may result in numbers below 0.

Time frame:
End of Period (includes both Visits 6 and 11)
Reported as:
Least squares mean · units on a scale
Euro QoL-5 Dimensions (EQ-5D) - Health State Profile Utility Scores at the End of Each Treatment Period (Week 6 of Each Treatment Period)
units on a scalePregabalinPlacebo
Index score Dolan 19970.649 ± 0.0150.643 ± 0.015
Index score Dolan 20010.650 ± 0.0140.641 ± 0.014
Statistical analysis
  • Pregabalin vs Placebo · Linear mixed effects model · p = 0.71107 (Secondary analysis was two-sided and performed at the 0.05 significance level. No corrections to alpha to control for potential inflation of Type I error resulting from multiple comparisons were made.) · Mean difference (final values): 0.006 · 95% CI -0.025 to 0.037
  • Pregabalin vs Placebo · Linear mixed effects model · p = 0.53965 (Secondary analysis was two-sided and performed at the 0.05 significance level. No corrections to alpha to control for potential inflation of Type I error resulting from multiple comparisons were made.) · Mean difference (final values): 0.009 · 95% CI -0.021 to 0.039

Adverse events

Collected over From the time that the participants were provided the informed consent document through and including 28 calendar days after the last administration of the study drug.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pregabalin—9/198 (4.5%)53/198 (26.8%)
Placebo—2/186 (1.1%)38/186 (20.4%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventPregabalinPlacebo
Urinary tract infectionInfections and infestations0/1981/186
Deep vein thrombosisVascular disorders0/1981/186
Angina unstableCardiac disorders1/1980/186
Myocardial infarctionEndocrine disorders1/1980/186
CellulitisInfections and infestations1/1980/186
DiverticulitisInfections and infestations1/1980/186
UrosepsisInfections and infestations1/1980/186
HypoglycaemiaMetabolism and nutrition disorders1/1980/186
Back painMusculoskeletal and connective tissue disorders1/1980/186
Muscular weaknessMusculoskeletal and connective tissue disorders1/1980/186
Most frequent other events
Showing 10 of 13
Most frequent other events
EventPregabalinPlacebo
SomnolenceNervous system disorders12/1984/186
FatigueGeneral disorders11/1983/186
DizzinessNervous system disorders11/1986/186
Oedema peripheralGeneral disorders9/1982/186
Upper respiratory tract infectionInfections and infestations5/1988/186
HeadacheNervous system disorders5/1988/186
NauseaGastrointestinal disorders5/1986/186
DiarrhoeaGastrointestinal disorders2/1985/186
Dry mouthGastrointestinal disorders5/1981/186
Weight increasedInvestigations5/1981/186

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Pregabalin/PlaceboPlacebo/PregabalinTotal
Mean59.1 ± 8.558.4 ± 9.358.7 ± 8.9
Sex: Female, Male
Sex: Female, Male(Participants)Pregabalin/PlaceboPlacebo/PregabalinTotal
Female403171
Male6171132
08

Study locations

45 sites
  • Dedicated Clinical Research
    Goodyear, Arizona 85395, United States
  • Arizona Research Center
    Phoenix, Arizona 85023, United States
  • Neuro-Pain Medical Center
    Fresno, California 93710, United States
  • HealthCare Partners Medical Group
    Los Angeles, California 90015, United States
  • IDS Pharmacy
    Los Angeles, California 90033, United States
  • University of Southern California
    Los Angeles, California 90033, United States
  • PAB Clinical Research
    Brandon, Florida 33511, United States
  • Pulmonary Associates of Brandon
    Brandon, Florida 33511, United States
  • Innovative Research of West Florida, Inc.
    Clearwater, Florida 33756, United States
  • The Office of Laszlo Jozef Mate, MD
    North Palm Beach, Florida 33408, United States
  • Meridien Research
    Tampa, Florida 33606, United States
  • Metabolic Research Institute, Inc.
    West Palm Beach, Florida 33401, United States
  • Clinical Research of Central Florida
    Winter Haven, Florida 33880, United States
  • Columbus Research Foundation
    Columbus, Georgia 31904, United States
  • MediSphere Medical Research Center, LLC
    Evansville, Indiana 47714, United States
  • Heartland Research Associates, LLC
    Wichita, Kansas 67205, United States
  • Quality Clinical Research, Inc.
    Omaha, Nebraska 68114, United States
  • Desert Endocrinology Clinical Research Center
    Henderson, Nevada 89052, United States
  • Clinical Research Consortium
    Las Vegas, Nevada 89119, United States
  • The Office of Dr. Stephen H. Miller, MD
    Las Vegas, Nevada 89144, United States
  • The Medical Research Network, LLC
    New York, New York 10128, United States
  • Neurology and Neuroscience Center of Ohio
    Toledo, Ohio 43623, United States
  • Sooner Clinical Research
    Oklahoma City, Oklahoma 73112, United States
  • The Office of Veronique Sebastian, MD
    Oklahoma City, Oklahoma 73120, United States
  • Sunstone Medical Research, LLC
    Medford, Oregon 97504, United States
  • Oregon Health and Science University - Comprehensive Pain Center
    Portland, Oregon 97239, United States
  • Oregon Health and Science University - Department of Anesthesiology and Perioperative Medicine
    Portland, Oregon 97239, United States
  • Blair Orthopedic Associates, Inc.
    Altoona, Pennsylvania 16602, United States
  • Altoona Center for Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • Memorial Hospital of Rhode Island
    Pawtucket, Rhode Island 02860, United States
  • Neurology and Pain Clinic, LLC
    Orangeburg, South Carolina 29118, United States
  • Houston Neurocare
    Houston, Texas 77030, United States
  • Centex Research, Inc.
    Houston, Texas 77062, United States
  • Eastern Virginia Medical School
    Norfolk, Virginia 23507, United States
  • Privatni specializovana ambulance pro neurologii a detskou neurologii
    Brno-Bystrc, 635 00, Czechia
  • Clintrial, s.r.o.
    Praha 10, 100 00, Czechia
  • Fakultni nemocnice v Motole
    Praha 5, 150 06, Czechia
  • Dr DR Lakha's Practice
    Johannesburg, Gauteng 1829, South Africa
  • Dr Hemant Makan (Private Practice)
    Lenasia, Gauteng 1820, South Africa
  • Randles Road Medical Centre
    Durban, Kwa-Zulu Natal 4000, South Africa
  • Richards Bay Trial Centre
    Richards Bay, 3900, South Africa
  • Forskningsmottagningen Gamla Sjukhuset i Falkoping
    Falkoping, 521 43, Sweden
  • Center for Lakemedelsstudier
    Malmo, 211 52, Sweden
  • Citydiabetes
    Stockholm, 111 57, Sweden
  • Bragee Medect AB
    Stockholm, 115 22, Sweden
09

References and documents

Publications

  • Huffman C, Stacey BR, Tuchman M, Burbridge C, Li C, Parsons B, Pauer L, Scavone JM, Behar R, Yurkewicz L. Efficacy and Safety of Pregabalin in the Treatment of Patients With Painful Diabetic Peripheral Neuropathy and Pain on Walking. Clin J Pain. 2015 Nov;31(11):946-58. doi: 10.1097/AJP.0000000000000198. PubMed 25565583 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2011, a primary completion of Jul 2013 and a completion of Jul 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2014, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2011
First posted
Nov 18, 2011
Start
Oct 2011
Primary completionActual
Jul 2013
CompletionActual
Jul 2013
Results first posted
Nov 18, 2014
Last update
Jan 28, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01474772
Responsible party
Sponsor
First posted
Nov 18, 2011
Start date
Oct 2011
Primary completion
Jul 2013
Completion
Jul 2013
Results posted
Nov 18, 2014
Last update
Jan 28, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pregabalin

Start the discussion